Alkermes plc
Open
$43.93
Prev. Close
$43.90
High
$44.08
Low
$43.93
Market Snapshot
$7.35B
48.1
2.23
$1.56B
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,050 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Recently from Cashu
Alkermes Awarded Orphan Drug Status for Alixorexton to Treat Idiopathic Hypersomnia
Alkermes plc (Ticker: ALKS) recently celebrates a crucial achievement with the US FDA granting orphan drug designation for alixorexton, a treatment designed for idiopathic hypersomnia. This rare and d…
Alkermes Reports 28.2% Revenue Growth, Analysts Bullish on Future Performance and Innovations
Alkermes plc (Ticker: ALKS) is making headlines due to impressive revenue growth and optimism surrounding its innovative treatments. The company announces a remarkable 28.2% revenue increase for the q…
Alkermes Highlights Real-World Benefits of Psychiatric Treatments at Major Healthcare Conferences
In the past few days, Alkermes plc (Ticker: ALKS) showcases its commitment to advancing psychiatry treatments with the recent presentation of new clinical and real-world data surrounding its psychiatr…
Alkermes Launches Brilliance Phase 3 Program for Narcolepsy Treatment with Alixorexton
Alkermes plc announces a significant development in its research pipeline with the launch of the Brilliance phase 3 program, which targets narcolepsy treatment through its oral orexin 2 receptor agoni…